Invest in Fore Genomics

Fore’s first product is the most comprehensive genetic screening service designed for healthy newborns, infants, and children to understand and manage their risk of disease.

Fore's Genetic Health Screen offers disease screening for genetically linked and treatable diseases, medication screening to provide information on how a child will respond to common medications, and on-demand access to genetic counseling. 

With Fore, parents receive yearly updates on their child's genomic insights, genetic counseling, and exclusive tailored content for their age group until the age of 18.

OPPORTUNITY: Industry, Problem & Solution

A significant opportunity exists in the pediatric preventative health space that aligns with the healthcare migration to preventative care and “Population Health.” 

Fore takes advantage of 20+ years of genomics research and proven clinical application to deliver predisposition genetic tests. Over 30M people in the US have a genetic disease and the ability to proactively diagnose a genetic disease can lead to active management and symptom mitigation.  

With 4M births annually and 20M children under the age of five, Fore has an early-mover advantage with a large market opportunity.

Disease screening is one of public health’s most successful programs. State mandated newborn screening is today’s pediatric screening solution, the number of conditions vary by state but on average they screen for under 20 conditions. There is no monitoring function with newborn screening and states face budget limitations to expand the test to include all conditions that should be screened. Fore Genomics provides a private option to screen for hundreds of diseases with enhanced newborn screening. 

BASIC STRATEGY: Mission, Vision, Product & Market

Fore has built full clinic activation, patient-initiated telemedicine, and strategic partner marketing channels with the ability to scale with revenue and/or investment.

Fore is in the process of expanding its test offerings with a test designed for adults planned to launch by YE 2024.

Fore’s vision is every person who wants personalized healthcare has a complete sequence of their DNA enabling precision medical care for their individual needs.

Fore's first product launched at the end of 2023 and we have beta users with $150,000 in reservations from expecting parents. 

USE OF CAPITAL: Marketing, Sales & Operations

Fore has solved all critical near-term marketing, sales and operations required to scale and is actively seeking seed funding to be used to accelerated commercialization of our Genetic Health Screening product. Please visit www.foregenomics.com for more information.